S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:ANEB

Anebulo Pharmaceuticals News Headlines

$7.20
+0.02 (+0.28 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.05
$7.20
50-Day Range
$6.55
$7.32
52-Week Range
$6.31
$9.33
Volume2,715 shs
Average Volume15,200 shs
Market Capitalization$168.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Media Mentions By Week

Anebulo Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ANEB
News Sentiment

0.61

0.35

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ANEB Articles
This Week

5

1

ANEB Articles
Average Week

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.

Anebulo Pharmaceuticals (NASDAQ ANEB) News Headlines Today

SourceHeadline
MarketBeat logoAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Large Decline in Short Interest
americanbankingnews.com - October 16 at 2:44 AM
marketwatch.com logoAnebulo Pharmaceuticals Shares Rise 7% After New Patent
marketwatch.com - October 13 at 2:53 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose
finance.yahoo.com - October 13 at 9:52 AM
finance.yahoo.com logoOverdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem
finance.yahoo.com - October 12 at 1:42 PM
finance.yahoo.com logoAnebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City
finance.yahoo.com - October 5 at 12:17 PM
MarketBeat logoAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Growth in Short Interest
americanbankingnews.com - October 3 at 1:54 AM
finance.yahoo.com logoThe Unintended Consequences of Ever-Increasing Marijuana Potency
finance.yahoo.com - September 27 at 12:56 PM
MarketBeat logoAnebulo Pharmaceuticals (NASDAQ:ANEB) Posts Earnings Results, Misses Expectations By $1.56 EPS
americanbankingnews.com - September 24 at 7:32 AM
benzinga.com logoCBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
benzinga.com - September 23 at 10:57 AM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update
finance.yahoo.com - September 22 at 7:13 PM
finance.yahoo.com logoCannabis Edibles are Leading to More Negative Outcomes in Cannabis Users
finance.yahoo.com - September 20 at 3:23 PM
finance.yahoo.com logoCB1 Antagonists as a Solution to the Complicated Problems of Cannabis Over-intoxication
finance.yahoo.com - September 13 at 5:07 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial
finance.yahoo.com - September 13 at 8:37 AM
finance.yahoo.com logoAnebulo is Developing an Antidote to Cannabis Intoxication
finance.yahoo.com - September 7 at 3:32 PM
finance.yahoo.com logoAnebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 7 at 3:32 PM
finance.yahoo.com logoCannabis Legalization is Driving an Increase in Related ER Visits
finance.yahoo.com - August 23 at 3:56 PM
finance.yahoo.com logoAlcohol, Cannabis and Synergistic Risk
finance.yahoo.com - August 16 at 4:16 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members
finance.yahoo.com - August 12 at 4:55 PM
finance.yahoo.com logoCannabis Over-Intoxication Results in Millions of Visits to the ER per Year
finance.yahoo.com - August 9 at 2:59 PM
finance.yahoo.com logoHere's What Anebulo Pharmaceuticals, Inc.'s (NASDAQ:ANEB) Shareholder Ownership Structure Looks Like
finance.yahoo.com - August 8 at 12:16 PM
finance.yahoo.com logoThe Underappreciated Risk Of Pediatric Cannabis Overdose
finance.yahoo.com - August 3 at 6:43 PM
finance.yahoo.com logoThe Danger of Synthetic Cannabinoids
finance.yahoo.com - July 26 at 3:03 PM
finance.yahoo.com logoThe Dark Side of Cannabis Legalization and one Biotech Company's Solution
finance.yahoo.com - July 12 at 2:04 PM
feeds.benzinga.com logoCannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials
feeds.benzinga.com - June 22 at 11:00 AM
msn.com logoBRIEF-Anebulo Pharmaceuticals Says On Track To Commence Phase 2 Proof-Of-Concept Clinical Trial With Aneb-001 In Q4
msn.com - June 21 at 7:45 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results
finance.yahoo.com - June 21 at 7:45 PM
reuters.com logoAnebulo Pharmaceuticals Inc
reuters.com - June 15 at 5:27 PM
finance.yahoo.com logoAnebulo Pharmaceuticals Announces Pricing of Initial Public Offering
finance.yahoo.com - June 7 at 8:29 AM
Get Anebulo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.